Pacific Biosciences of California (PACB) closed at $2.21 in the latest trading session, marking a -5.96% move from the prior ...

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.

Good afternoon, everyone. And welcome to the PacBio First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there ...

In a report released today, Luke Sergott from Barclays maintained a Hold rating on Pacific Biosciences (PACB – Research Report), with a price target of $2.00. The company’s shares closed yesterday at ...

Pacific Biosciences PACB underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. With the Martin ...

In the latest close session, Pacific Biosciences of California (PACB) was up +2.4% at $2.13. The stock outperformed the S&P 500, which registered a daily loss of 0.34%. Elsewhere, the Dow lost 0.94%, ...

Good day, and welcome to the PacBio Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to ...